Samantha Butzke, MD
Pediatric Gastroenterology · Annapolis, MDNPI 1780114967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,645, more than ten times the $14 reported in 2022.
Across 258 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$741
- Regeneron Healthcare Solutions, Inc.$645
- Johnson & Johnson$612
- Sanofi$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$298
- Ardelyx, Inc.$277
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,205100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $741 |
| Regeneron Healthcare Solutions, Inc. | 32 | $645 |
| Johnson & Johnson | 28 | $612 |
| Sanofi | 17 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $298 |
| Ardelyx, Inc. | 11 | $277 |
| Madrigal Pharmaceuticals | 12 | $261 |
| Phathom Pharmaceuticals, Inc. | 21 | $247 |
| Lilly USA, LLC | 7 | $185 |
| Ipsen Biopharmaceuticals, Inc | 8 | $171 |
| AbbVie | 7 | $150 |
| QOL Medical, LLC | 11 | $138 |
| Celltrion USA Inc. | 7 | $133 |
| Pharmacosmos Therapeutics Inc. | 5 | $119 |
| Ironwood Pharmaceuticals, Inc | 6 | $98 |
| Alnylam Pharmaceuticals Inc. | 6 | $96 |
| Stryker | 3 | $84 |
| Merck | 5 | $82 |
| Intercept Pharmaceuticals, Inc. | 3 | $67 |
| Bristol Myers Squibb | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $38 |
| Organon | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $28 |
| Digestive Care, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Amgen | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Orphalan Inc | 1 | $16 |
How this compares
$5,205 in reported general payments places this provider in the 85th percentile of 28 pediatric gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric gastroenterology in Annapolis
- Sara SmithBaltimore$27K
- Wikrom KarnsakulBaltimore$23K
- Steven CzinnBaltimore$10K
- Maria Oliva-HemkerBaltimore$6K
- Samra BlanchardBaltimore$3K
- Atiye AktayBaltimore$898
- Lina Diaz CalderonBaltimore$670
- Howard KaderBaltimore$621
- Kenneth NgBaltimore$542
- Boram JiGlen Burnie$329
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.